AtriCure (NASDAQ:ATRC) Hits New 52-Week High - What's Next?

Key Points

• AtriCure shares reached a new 52-week high of $55.94 and last traded at $55.50, up from a prior close of $54.54.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $52.00; Piper Sandler recently raised its target to $60.00.
• The company reported quarterly revenue of $153.6 million, exceeding estimates, and EPS of $0.18 versus a loss of $0.13 a year earlier. However, insiders have sold 65,036 shares worth approximately $2.76 million over the past 90 days.

Shares of AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) reached a new 52-week high on Monday . The company traded as high as $55.94 and last traded at $55.5010, with a volume of 34758 shares changing hands. The stock had previously closed at $54.54.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Piper Sandler increased their price target on shares of AtriCure from $50.00 to $60.00 and gave the stock an "overweight" rating in a report on Thursday, August 27th. BTIG Research increased their target price on shares of AtriCure from $45.00 to $55.00 and gave the stock a "buy" rating in a research note on Monday, August 24th. Raymond James Financial set a $52.00 price target on shares of AtriCure in a report on Tuesday, July 21st. Weiss Ratings upgraded shares of AtriCure from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, August 19th. Finally, Zacks Research cut shares of AtriCure from a "strong-buy" rating to a "hold" rating in a report on Monday, August 24th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, AtriCure has a consensus rating of "Moderate Buy" and an average target price of $52.00.

AtriCure Stock Up 0.9%

The stock's fifty day moving average price is $42.41 and its 200 day moving average price is $33.56. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. The stock has a market cap of $2.80 billion, a P/E ratio of 261.75 and a beta of 1.26.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The company had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. During the same period in the previous year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, research analysts forecast that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Maggie Yuen sold 3,500 shares of the firm's stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total transaction of $134,470.00. Following the transaction, the director directly owned 14,015 shares of the company's stock, valued at approximately $538,456.30. This trade represents a 19.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Karl S. Dahlquist sold 9,370 shares of the business's stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $48.89, for a total value of $458,099.30. Following the completion of the sale, the insider owned 87,319 shares of the company's stock, valued at $4,269,025.91. The trade was a 9.69% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 65,036 shares of company stock valued at $2,758,687. 4.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new stake in shares of AtriCure in the 2nd quarter valued at $125,198,000. Wellington Management Group LLP raised its position in AtriCure by 8.1% in the 3rd quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company's stock worth $151,296,000 after purchasing an additional 322,818 shares during the period. California State Teachers Retirement System lifted its stake in AtriCure by 2,627.3% in the second quarter. California State Teachers Retirement System now owns 1,634,927 shares of the medical device company's stock worth $45,745,000 after purchasing an additional 1,574,980 shares during the last quarter. First Light Asset Management LLC lifted its stake in AtriCure by 32.0% in the fourth quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company's stock worth $46,501,000 after purchasing an additional 285,083 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in AtriCure by 8.2% during the first quarter. Dimensional Fund Advisors LP now owns 997,759 shares of the medical device company's stock valued at $28,466,000 after buying an additional 75,862 shares during the period. 99.11% of the stock is owned by hedge funds and other institutional investors.

About AtriCure

AtriCure, Inc NASDAQ: ATRC is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.